Advertisement

Steric Stabilization of Liposomes Containing Amphotericin B: A Future Direction in Antifungal Therapy?

  • Els W. M. van Etten
  • Irma A. J. M. Bakker
Part of the Biotechnology Intelligence Unit book series (BIOIU)

Abstract

In the past ten years lipid formulations of amphotericin B (AMB) have been developed by the pharmaceutical industry with the primary aim of reduction of AMB’s toxicity. At present, three different industrially produced AMB-lipid formulations are available, with substantial lower toxicity than conventional AMB (Fungizone®). One formulation is AmBisome®, and is discussed in chapter 13 of this book.

Keywords

Antifungal Activity Invasive Fungal Infection Liposomal Amphotericin Mononuclear Phagocyte System Uninfected Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome®, a unilammelar formulation of amphotercin B. J Liposome Res 1993; 3: 429–450.Google Scholar
  2. 2.
    Bakker-Woudenberg IAJM, Lokerse AF, Ten Kate MT, Mouton JW, Woodle MC, Storm G: Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae infected lung tissue. J Infect Dis 1993; 168: 164–171.Google Scholar
  3. 3.
    AmBisome® Liposomal Amphotericin B, Product Monograph. NeXstar Pharmaceuticals, Inc. 1994.Google Scholar
  4. 4.
    Van Etten EWM, Van Vianen W, Tijhuis RHG, Storm G, and Bakker-Woudenberg IAJM. Sterically stabilized amphotericin B-liposomes: toxicity and biodistribution in mice. J Control Release 1995; 37: 123–129.Google Scholar
  5. 5.
    Van Etten EWM, Otte-Lambillion M, Van Vianen W, Ten Kate MT, BakkerWoudenberg IAJM. Biodistribution of liposomal amphotericin B (AmBisome) versus amphotericin B-desoxycholate (Fungizone) in immunocompetent uninfected mice as well as in leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995; 35:509-519.Google Scholar
  6. 6.
    Van Etten EWM, Ten Kate MT, Stearne-Cullen LET, Bakker-Woudenberg IAJM: Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995; 39: 1954–1958.Google Scholar
  7. 7.
    Leenders ACAP, De Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996; 10: 1570–1575.Google Scholar
  8. 8.
    Van Etten EWM, Snijders SV, Verbrugh HA, Bakker-Woudenberg IAJM. Efficacy of pegylated long circulating amphotericin B-liposomes versus AmBisome® in the treatment of systemic candidiasis in leukopenic mice in relation to the severity of infection. (manuscript in preparation)Google Scholar
  9. 9.
    Leenders ACAP, de Marie S, Ten Kate MT, Bakker-Woudenberg IAJM, and Verbrugh HA. Liposomal amphotericin B (AmBisome®) reduces dissemination of infection as compared to amphotercin B deoxycholate (Fungizone®) in a newly developed animal model of one-sided pulmonary aspergillosis. J Antimicrob Chemother 1996; 38: 215–225.Google Scholar
  10. 10.
    Van Etten EWM, Stearne-Cullen LET, Snijders SV, Verbrugh HA, BakkerWoudenberg IAJM. Efficacy of pegylated long circulating amphotericin B-liposomes in the treatment of pulmonary aspergillosis in leukopenic rats. (Manuscript in preparation).Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Els W. M. van Etten
    • 1
  • Irma A. J. M. Bakker
    • 1
  1. 1.WoudenbergNetherlands

Personalised recommendations